Glutathione peroxidase 3 is a novel clinical diagnostic biomarker and potential therapeutic target for neutrophils in rheumatoid arthritis
Authors' conclusion
This research recognized hub genes and explored the characteristics of neutrophils in RA. Our findings suggest that the novel hub gene GPX3 is involved in the neutrophil-driven oxidative stress-mediated pathogenesis of RA.
Study context
- Population
- Neutrophils from synovial fluid and peripheral blood of rheumatoid arthritis (RA) patients and peripheral blood of healthy controls
- Comparison
- Neutrophils from RA synovial fluid (SF) vs peripheral blood of RA patients and healthy controls
- Outcome
- Hub genes in neutrophils for diagnosis and treatment of RA
Methodological detailsbioinformatic analysis of publicly available GEO datasets, weighted gene co-expression network analysis, flow cytometry
- Bioinformatic analysis of publicly available GEO datasets
- Weighted gene co-expression network analysis
- Flow cytometry
Main finding
As reported in the abstract
- Neutrophils in RA SF underwent transcriptional changes, different from peripheral blood of healthy controls or RA patients; glycolysis, HIF-1 signaling, NADH metabolism and oxidative stress affected
- Hub genes strongly linked with glycolysis-related genes (ENO1, GAPDH, PKM) responsible for reactive oxygen species (ROS) production
- Antioxidant enzyme GPX3, a ROS scavenger, first identified as a hub gene in RA neutrophils
- Neutrophils from patients with autoinflammatory and autoimmune diseases had markedly enhanced ROS levels, most notably in RA SF
Original publication
Glutathione peroxidase 3 is a novel clinical diagnostic biomarker and potential therapeutic target for neutrophils in rheumatoid arthritis. Arthritis Res Ther. Published 22 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →